Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)

阶段(地层学) 肿瘤科 临床试验 IGHV@ 生存分析 化学免疫疗法 比例危险模型 危险系数 队列 临床研究阶段 累积发病率
作者
Manuela Bergmann,Raymonde Busch,Barbara Eichhorst,Andreas Buehler,Norbert Fischer,Michael J. Eckart,Ursula Vehling-Kaiser,Ulrich Jäger,Georg Hopfinger,Clemens M. Wendtner,Kirsten Fischer,Bertold Emmerich,Hartmut Döhner,Michael Hallek,Stephan Stilgenbauer
出处
期刊:Blood [American Society of Hematology]
卷期号:122 (21): 4127-4127 被引量:4
标识
DOI:10.1182/blood.v122.21.4127.4127
摘要

Introduction Chronic lymphocytic leukemia (CLL) is typically diagnosed at an early stage and a watch & wait (W&W) strategy is applied. Only when the disease progresses to a more active, symptomatic form, treatment is indicated. The prospective CLL1 trial was designed to evaluate the benefit of early risk-adapted therapy with fludarabine (F) monotherapy, and to document the natural course of the disease from diagnosis. Here we present follow-up data to assess overall survival from the time point of treatment indication. Methods At enrolment, risk stratification was performed based on bone marrow (BM) infiltration pattern, lymphocyte doubling time (LDT), serum beta2-microglobulin (s2-MG), and serum thymidine kinase (TK). Pts were “high-risk” (HR) if they had diffuse BM infiltration pattern and/or LDT 7.0 U/L and/or s2-MG >3.5 mg/L at enrolment. HR pts were randomized in a 1:1 ratio to early F (HR-F), or to W&W until classical treatment indication (HR-W&W), which was also applied to all low-risk (LR) pts. Results Between 1997 and 2004, 710 pts with Binet A stage CLL were enrolled and underwent risk stratification (RS) per protocol. Median time from diagnosis to enrolment was 3.2 mo (range 0-33.7) and median follow-up time was 8.5 years (yrs) (range 0-13.9). 521 pts (73%) were stratified to LR and 189 pts (27%) to HR, of whom 93 pts (49%) were randomized to HR-F and 96 pts (51%) to HR-WW high-risk cytogenetic features (17p- and 11q-) had 3% and 8% of pts, respectively. Early intervention with F among HR pts significantly prolonged progression-free survival (PFS) (30 vs. 13 mo; p 3.5 mg/L, and age >60 yrs as independent prognostic factors for OS for patients with progressive, active disease and treatment indication. Conclusions Monotherapy with fludarabine is not superior to the W&W approach for the management of early stage CLL pts, since early F did not improve OS or outcome following subsequent therapies. Disclosures: No relevant conflicts of interest to declare.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
桃儿完成签到 ,获得积分10
5秒前
扬帆起航完成签到 ,获得积分10
11秒前
开放又亦完成签到 ,获得积分10
17秒前
依依完成签到,获得积分10
34秒前
mc1220完成签到,获得积分10
45秒前
czj完成签到 ,获得积分10
55秒前
kuyi完成签到 ,获得积分10
55秒前
像猫的狗完成签到 ,获得积分10
56秒前
Julien完成签到,获得积分10
1分钟前
沉静香氛完成签到 ,获得积分10
1分钟前
尼可刹米洛贝林完成签到,获得积分10
1分钟前
刘荻萩完成签到 ,获得积分10
1分钟前
今后应助狼来了aas采纳,获得10
1分钟前
x银河里完成签到 ,获得积分10
1分钟前
a46539749完成签到 ,获得积分10
1分钟前
一一完成签到,获得积分10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
研友_VZG7GZ应助科研通管家采纳,获得10
1分钟前
nanfeng完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
金光一闪发布了新的文献求助10
1分钟前
狼来了aas发布了新的文献求助10
1分钟前
rumengzhuo完成签到,获得积分10
1分钟前
gyx完成签到 ,获得积分10
1分钟前
金光一闪完成签到,获得积分10
1分钟前
二十八完成签到 ,获得积分10
1分钟前
zx完成签到 ,获得积分10
1分钟前
彩色的芷容完成签到 ,获得积分10
1分钟前
乐观的星月完成签到 ,获得积分10
2分钟前
eternal_dreams完成签到 ,获得积分10
2分钟前
西安浴日光能赵炜完成签到,获得积分10
2分钟前
vagabond完成签到 ,获得积分10
2分钟前
2分钟前
XQ完成签到,获得积分10
2分钟前
Wang发布了新的文献求助10
2分钟前
liars完成签到 ,获得积分10
2分钟前
juliar完成签到 ,获得积分10
2分钟前
迅速千愁完成签到 ,获得积分10
2分钟前
fawr完成签到 ,获得积分10
2分钟前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
Typology of Conditional Constructions 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3571332
求助须知:如何正确求助?哪些是违规求助? 3141926
关于积分的说明 9444874
捐赠科研通 2843331
什么是DOI,文献DOI怎么找? 1562830
邀请新用户注册赠送积分活动 731326
科研通“疑难数据库(出版商)”最低求助积分说明 718524